Vanguard Capital Management
CLYM

Vanguard Capital Management’s Climb Bio CLYM Stock Holding History

Vanguard Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Buy
1,698,654
+519,995
+44% +$5.37M ﹤0.01% 2388
2026
Q1 		$8.07M Buy
+1,178,659
New +$6.8M ﹤0.01% 2849

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management's CLYM Position: Q2 2026 in Review

Vanguard Capital Management increased its Climb Bio (CLYM) stake by 44% in Q2 2026, buying an estimated $5.37M and bringing the position to 1,698,654 shares worth $22.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2388.

Vanguard Capital Management first reported a position in CLYM in Q1 2026 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Vanguard Capital Management held 1,698,654 shares of Climb Bio worth $22.2M as of Q2 2026.
  • Vanguard Capital Management bought 519,995 Climb Bio shares in Q2 2026, an estimated $5.37M.
  • Climb Bio made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2388 holding.
  • Vanguard Capital Management first reported a position in Climb Bio in Q1 2026 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.